Enzychem Lifesciences

At a glance

Enzychem Lifesciences filed 79 disclosures in the last 12 months, including 14 5% holder, 4 buyback and 2 insider. The most recent key filing was on Oct 15: A major holder's stake rose from 21.61% to 21.61% (pledge).

Revenue for 2025 was ₩67.8B, down 12.4% on 2024. It made an operating loss of ₩14.3B. Debt was 7% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩38.4B and operating loss of ₩7.3B.

The 2025 annual report lists 116 employees with an average tenure of 3.4 years and average pay of ₩48.4M, #1519 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩470M each on average. It paid no cash dividend for 2025. 주식회사 브리짓라이프사이언스 and related parties held 12.35% at year end.

Of 1 recent 5%+ holder report, 0 raised and 0 cut a stake; the largest stake reported was 21.61% on Oct 15.

From the 2025 annual report

Staff: 116 (62 men, 54 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩5.6B. Directors and auditors: 5, paid ₩2.4B in total.

No cash dividend was paid for 2025.

Largest shareholder

주식회사 브리짓라이프사이언스 holds 7.46%; with 4 related parties the group holds 12.35% of common shares at year end (from 12.32% at the start of the year).

Individuals paid ₩500M or more

Auditor: 이촌회계법인 · opinion: Disclaimer of opinion.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports